Milsaperidone

Vanda Pharmaceuticals is running a Phase 3 trial of milsaperidone as add-on therapy for adults with major depressive disorder who have not responded adequately to standard antidepressants [1]. Milsaperidone is not a new molecule, and as of February 20, 2026 it is no longer an investigational one either: the FDA approved it as BYSANTI for schizophrenia and acute bipolar I disorder under NDA 220358 [2]. That approval matters for the MDD program because it confirms the FDA accepted the molecule's safety and CMC package, leaving the Phase 3 MDD trial as a label-expansion study of an approved drug rather than a de novo development bet. Milsaperidone is the major active metabolite of iloperidone (Vanda's existing schizophrenia and bipolar I drug, Fanapt), and Vanda is positioning it as a more selective version of the parent compound. The commercial logic is straightforward: adjunctive atypical antipsychotics in MDD are a multi-billion dollar category dominated by Rexulti (brexpiprazole) and Vraylar (cariprazine), and even a niche position would meaningfully shift Vanda's revenue trajectory off a Fanapt baseline of $117.3M in 2025 [10]. The trial (NCT06830044, target n=500) is recruiting with change in MADRS, the standard depression rating scale, as the primary endpoint [1].

NCT06830044 is enrolling 500 adult MDD patients with inadequate response to ongoing antidepressant therapy, randomized to milsaperidone or placebo with MADRS as the primary outcome [1]. No public breakthrough, fast track, or orphan designations apply, this is a standard regulatory path. Milsaperidone has well-characterized pharmacology in humans through its parent iloperidone and now through its own approved label for schizophrenia and bipolar I disorder, which removes PK and basic tolerability uncertainty before any key MDD data lands. Drugs@FDA application 220358 (BYSANTI, milsaperidone) was approved on February 20, 2026 for adult schizophrenia and acute manic or mixed episodes of bipolar I disorder [2]. The MDD Phase 3 is therefore a label-expansion program for an approved molecule, not a first approval bid. A realistic readout timeline given recruiting status and chronic outpatient enrollment: top-line in late 2027 or 2028, with a supplemental NDA to follow. Whether the program was supported by a dedicated Phase 2 MDD study or moved straight to Phase 3 on the strength of iloperidone metabolite pharmacology has not been disclosed in Vanda's public filings; the absence of a published Phase 2 MDD readout is itself a soft caution flag. Vanda's 8-K filings from February and April 2026 cover the BYSANTI approval and commercial launch; the October 2025 8-K predates the approval [3][4]. The company's 10-Q from July 2025 carries milsaperidone as an active R&D line item without granular cost or enrollment disclosure [5].

Atypical antipsychotics in depression work mostly through serotonin 5-HT2A blockade (the 5-HT2A receptor sits on cortical neurons and, when blocked, lifts dopamine release in the prefrontal cortex, the part of the brain involved in motivation and cognition) combined with action at dopamine D2 receptors. Iloperidone and milsaperidone are D2 antagonists. Three of the four approved adjunctive atypicals (Abilify/aripiprazole, Rexulti/brexpiprazole, and Vraylar/cariprazine) use D2 partial agonism instead, but the fourth, quetiapine (Seroquel XR), is a full D2 and 5-HT2A antagonist already approved as adjunctive MDD therapy. So full D2 antagonism in depression is not unprecedented and is not in itself a differentiator for milsaperidone. The relevant comparison is to quetiapine specifically: milsaperidone is differentiated from quetiapine by metabolite lineage (cleaner separation from iloperidone's parent profile) and potentially by a lighter sedation and metabolic burden, since quetiapine's adjunctive MDD use is constrained by sedation and weight gain that limit prescriber willingness in mildly to moderately depressed patients. The class is commercially validated: four atypicals are FDA approved as adjunctive MDD therapy, and Otsuka's Rexulti franchise generated roughly $1.6B in 2024 sales [6]. Open Targets links HTR2A to MDD with an evidence score of 0.70, among the strongest psychiatric target associations in their database [7]. The mechanism is not novel and not speculative. The question milsaperidone has to answer is not 'does the class work' (it does) but 'does this specific molecule offer something the four already-approved adjunctive atypicals don't,' whether that's a cleaner side effect profile, a faster onset, or a better response in a specific patient subgroup.

NCT06830044 is a placebo-controlled adjunctive trial in adults with MDD who continue to have inadequate response to their current antidepressant [1]. Primary endpoint: change from baseline in MADRS, the 10-item clinician-rated depression scale that the FDA accepts as the regulatory standard in this indication. Target enrollment: 500. The design is standard for the indication, and it inherits the standard problem. Placebo response in adjunctive MDD trials routinely improves 5 to 7 MADRS points on its own, so the active drug typically has to clear a 2-point or larger separation to be statistically and clinically convincing. From Rexulti's FDA-approved key trials: Study 1 (2 mg/day) showed roughly a 3.2-point MADRS separation versus placebo, and Study 2 (1 mg/day) showed about a 1.3-point placebo-subtracted difference [11]. Vraylar's two adjunctive MDD trials cluster in a similar 1.5 to 2.8 point range across doses. That is the empirical bar milsaperidone has to clear. The trial does not use biomarker selection or genetic enrichment, which is normal for psychiatric trials but means any responder subgroup has to emerge from the overall population analysis. Dose-finding rationale from Phase 2 has not been disclosed in detail in public filings. Recruitment is open, and there is no public data on enrollment pace, dropout rates, or interim safety signals.

Milsaperidone is FDA-approved (BYSANTI, 2026-02-20). BioCosm's model estimates a drug's first FDA approval, which has already happened here, so no probability is shown - any current trial is a new-indication study.

Efficacy risk is the placebo problem, which has killed more adjunctive MDD programs than any single mechanism issue. Patients enter these trials still on a partially-working antidepressant, and the placebo arm routinely picks up 5 to 7 MADRS points just from extra clinical attention and time. Safety risk centers on the class: akathisia (a restless agitation that patients describe as the worst side effect of these drugs), weight gain, metabolic disruption, and sedation are why prescribers hesitate to add an atypical to a depressed patient. Iloperidone's label specifically warns about QTc prolongation, with a thorough QT study showing roughly a 9 msec mean increase at 12 mg twice daily and about 19 msec when both CYP2D6 and CYP3A4 are inhibited [9]. Milsaperidone's own FDA-approved label (BYSANTI) carries the BYSANTI safety profile from the schizophrenia and bipolar I package, which should be referenced once available to readers for direct QTc comparison. Execution risk: Vanda is a small commercial company with a history of legal entanglement over Fanapt's market exclusivity and a sales force that has not historically commanded strong prescriber loyalty in the major psychiatric markets [5]. Commercial risk is sharp. Even if milsaperidone hits its primary endpoint, Rexulti and Vraylar dominate the adjunctive MDD space with established formulary positions. Brexpiprazole generic timing is uncertain: a generic was tentatively approved (Alembic, January 2025) but the Orange Book formulation patent on Rexulti runs to October 2032, and the broader patent estate could extend protection into 2033 depending on Hatch-Waxman litigation outcomes [12]. So the price-pressure window for the class likely opens between 2028 and 2032 rather than firmly at 2028. Payers will almost certainly require step therapy through cheaper generic options before reimbursing a new branded adjunctive atypical.

Worth watching, but as a single-stock Vanda story rather than a category-defining asset. The mechanism is proven, the molecule is now FDA-approved for adjacent indications, the trial design is standard, the readout will be a clean MADRS separation read in 2027 or 2028, and the binary outcome maps directly to Vanda's revenue. The baseline matters here: Fanapt did $117.3M in 2025 (+24% YoY) and total company revenue was $216.1M [10], so even a modest adjunctive MDD launch could be material to Vanda. For investors already in VNDA, this is the central question for the next 18 to 30 months. For everyone else, the data point to wait for is the Phase 3 top-line: the MADRS effect size versus Rexulti's 1.3 to 3.2 point benchmark, and the akathisia and weight-gain discontinuation rates. If milsaperidone delivers a clear MADRS separation with cleaner tolerability than the incumbents, it carries a defensible niche even in a generic-pressured class. If the molecule underperforms on tolerability while only matching efficacy, it has no real commercial wedge. The next meaningful update is enrollment completion, which based on a 500-patient outpatient psychiatric trial typically takes 18 to 24 months from start of recruitment. Vanda's quarterly earnings calls are the most likely venue for that disclosure [3][4].